STN- Structure Search 10/20/06

10/522,646

=> d ibib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:128520 CAPLUS
DOCUMENT NUMBER: 144:362557
TITLE: Design and synthesis of potent and subtype-selective PPARα agonists
AUTHOR(S): Desai, Ranjit C.; Metzger, Edward; Santini, Conrad; Meinke, Peter T.; Heck, James V.; Berger, Joel P.; MacNaul, Karen L.; Cai, Tian-quan; Wright, Samuel D.; Agrawal, Arun; Moller, David E.; Sahoo, Soumya P.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1673-1678
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:362557
GI



I

AB Nonracemic aryloxypropoxyphenoxyisobutyric acids and aryloxypropoxyphenoxybutanoic acids such as I (RR1 = O or R = R1 = Me) are prepared as selective human PPARα agonists for use as antihypercholesteremic and hypolipemic agents; I (R = R1 = Me) is a particularly potent antihypercholesteremic and hypolipemic agent both alone and in combination with simvastatin. The aryloxypropoxyphenoxyisobutyric acids and aryloxypropoxyphenoxybutanoic acids are generated by structural modification of an aryloxypropoxyphenyl thiazolidinedione and replacement of the thiazolidinedione moiety with the carboxylic acid moiety present in fibrates. The effects of changes in both the substituents neighboring the carboxylic acid moiety and in the pendant aryl groups on the selectivity and affinity of aryloxypropoxyphenoxyisobutyric acids and aryloxypropoxyphenoxybutanoic acids for PPARα are determined The pharmacokinetics of I (R = R1 = Me; RR1 = O) in rats, dogs, and monkeys are determined

IT 653563-72-5P 653563-73-6P 882176-29-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of aryloxypropoxyphenylisobutyric and aryloxypropoxyphenylbutanoic acids as selective human PPARα agonists for use as hypolipemic and antihypercholesteremic agents)

RN 653563-72-5 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-diethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-73-6 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(1-methylethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 882176-29-6 CAPLUS
CN Butanoic acid, 2-[4-[3-[[2,2-dimethyl-4-[3-(trifluoromethyl)phenyl]-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 653563-66-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, selective human PPARα agonism, hypolipemic and antihypercholesteremic activities, and pharmacokinetics of nonracemic aryloxypropoxyphenylbutanoic acids)

RN 653563-66-7 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:100986 CAPLUS
DOCUMENT NUMBER: 140:157460
TITLE: PPARα-selective chromane and chromene compounds for the treatment of dyslipidemia and other lipid disorders, and preparation thereof
INVENTOR(S): Desai, Ranjit C.; Sahoo, Soumya
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010992	A1	20040205	WO 2003-US23499	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493913	AA	20040205	CA 2003-2493913	20030725
AU 2003256911	A1	20040216	AU 2003-256911	20030725
EP 1539137	A1	20050615	EP 2003-771947	20030725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538109	T2	20051215	JP 2004-524924	20030725
US 2006089404	A1	20060427	US 2005-522646	20050926
PRIORITY APPLN. INFO.:			US 2002-399518P	P 20020730
			WO 2003-US23499	W 20030725

OTHER SOURCE(S): MARPAT 140:157460
GI



I

AB A class of chromane and chromene compds. I [R1, R2, R4 = (un)substituted C1-3 alkyl; R3, R5, R7 = H, (un)substituted C1-3 alkyl; R6 = H, Cl, Me, CF3; A, B = H, Cl, F, Me, CF3; X, Y = O, S; n = 2, 3; dashed line = optional double bond], and pharmaceutically acceptable salts thereof, are useful as therapeutic compds., particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis. Compound preparation is included.

IT 653563-65-6P 653563-66-7P 653563-67-8P
653563-68-9P 653563-69-0P 653563-70-3P
653563-71-4P 653563-72-5P 653563-73-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPARα-selective chromane and chromene compds. for treatment of lipid disorders, preparation, and use with other agents)

RN 653563-65-6 CAPLUS

CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 653563-66-7 CAPLUS

CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-67-8 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-68-9 CAPLUS
CN Butanoic acid, 2-[4-[2-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]ethoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-69-0 CAPLUS
CN Butanoic acid, 2-[4-[3-[(6-chloro-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-7-yl)oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-70-3 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-ethyl- (9CI) (CA INDEX NAME)



RN 653563-71-4 CAPLUS
CN Butanoic acid, 2-[4-[2-[[6-chloro-2,2-dimethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]ethoxy]phenoxy]-2-ethyl- (9CI) (CA INDEX NAME)



RN 653563-72-5 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-diethyl-4-(trifluoromethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 653563-73-6 CAPLUS
CN Butanoic acid, 2-[4-[3-[[6-chloro-2,2-dimethyl-4-(1-methylethyl)-2H-1-benzopyran-7-yl]oxy]propoxy]phenoxy]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d re 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
RE
(1) Adams, A; Bioorg Med Chem Lett 2003, V12, P931
(2) Anum, E; Ann Epidemiol 2004, V14, P705
(3) Berger, J; J Biol Chem 1999, V274, P6718 CAPLUS
(4) Brown, P; Bioorg Med Chem Lett 2001, V11, P1225 CAPLUS
(5) Brown, P; J Med Chem 1999, V423, P3785
(6) Desai, R; WO 2004/010992 A1 CAPLUS
(7) Desai, R; Bioorg Med Chem Lett 2005, V13, P2795
(8) Desai, R; Bioorg Med Chem Lett 2005, V13, P3541
(9) Koyam, H; Bioorg Med Chem Lett 2005, V15, P3347
(10) Nomura, M; J Med Chem 2003, V46, P3581 CAPLUS
(11) Shi, G; J Med Chem 2005, V48, P5589 CAPLUS
(12) Staels, B; Circulation 1998, V89, P2088
(13) Staels, B; Curr Pharm Des 1997, V3, P1 CAPLUS
(14) The Cambridge Crystallographic Data Centre; www.ccdc.cam.ac.uk/data_request/cif
(15) Xu, Y; J Med Chem 2003, V46, P5121 CAPLUS

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
RE
(1) Merck & Co Inc; WO 0226729 A2 2002 CAPLUS
(2) Miyano; US 4565882 A 1986 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 11:26:53 ON 20 OCT 2006)

FILE 'REGISTRY' ENTERED AT 11:27:12 ON 20 OCT 2006
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 10 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:27:44 ON 20 OCT 2006
L4 2 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> => d his

```
     (FILE 'HOME' ENTERED AT 11:26:53 ON 20 OCT 2006)

     FILE 'REGISTRY' ENTERED AT 11:27:12 ON 20 OCT 2006
L1                STRUCTURE UPLOADED
L2              2 S L1
L3             10 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 11:27:44 ON 20 OCT 2006
L4              2 S L3

     FILE 'REGISTRY' ENTERED AT 11:28:35 ON 20 OCT 2006
L5                STRUCTURE UPLOADED
L6              0 S L5
L7              0 S L5 FULL

=> d l5
L5 HAS NO ANSWERS
L5                STR
```




```
G1 O,S


Structure attributes must be viewed using STN Express query preparation.


=>
```